GLP1R and chronic kidney disease: In this retrospective cohort study emulating the CREDENCE and DAPA-CKD trials and based on multi-institutional routine care data from Taiwan, patients with T2D and CKD stages 1 to 3 and newly receiving SGLT2 inhibitors had a lower incidence of composite anemia outcomes compared with those newly receiving GLP-1 RAs.